Israeli biotech startup CytoReason announced Wednesday that it is collaborating with German multinational science and technology company, Merck KGaA, Darmstadt, Germany, to profile one of its leading immuno-oncology drugs.
Read more here.
Israeli biotech startup CytoReason announced Wednesday that it is collaborating with German multinational science and technology company, Merck KGaA, Darmstadt, Germany, to profile one of its leading immuno-oncology drugs.
Read more here.
![[OurCrowd in Crowdfund Insider] OurCrowd partners with Singapore Economic Development Board](https://blog.ourcrowd.net/wp-content/themes/Extra/images/post-format-thumb-text.svg)
